Stock ANRO ALTO NEUROSCIENCE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Alto Neuroscience, Inc.

Equities

ANRO

US02157Q1094

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-31 pm EDT 		5-day change 1st Jan Change
11.96 USD -0.33% Intraday chart for Alto Neuroscience, Inc. -7.43% -.--%
May. 21 Alto Neuroscience, Inc. Appoints Michael Hanley as Chief Operating Officer CI
May. 14 Alto Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
BU
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
BU
Alto Neuroscience, Inc. Appoints Michael Hanley as Chief Operating Officer
CI
Alto Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
BU
Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
BU
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
BU
Alto Neuroscience, Inc. Announces Positive Phase 1 Results for ALTO-101, A Novel PDE4 Inhibitor in Development for Schizophrenia
CI
Alto Neuroscience Starts Phase 2 Trial of ALTO-203 in Major Depressive Disorder Patients
MT
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
BU
Alto Neuroscience, Inc. Announces Initiation of Phase 2 Study of Alto-203 in Patients with Major Depressive Disorder
CI
Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights
BU
Alto Neuroscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Alto Neuroscience, Inc.(NYSE:ANRO) added to S&P TMI Index
CI
Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
BU
Alto Neuroscience Appoints Maha Radhakrishnan to Board of Directors
CI
Alto Neuroscience to Participate in Upcoming Investor Conferences
BU
Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference
BU
Stifel Initiates Alto Neuroscience With Buy Rating, Price Target is $32
MT
Baird Initiates Alto Neuroscience With Outperform Rating, Price Target is $32
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANRO Stock
  4. News Alto Neuroscience, Inc.